Genencor is a biotechnology company based in Palo Alto, CA and a subsidiary of DuPont. Genencor is a leading producer of industrial enzymes and low-priced bulk protein. The name Genencor originates with Genencor, Inc., the original joint venture between Genentech and Corning Incorporated, which was founded in 1982. It is considered to have pioneered the field of industrial biotechnology, as distinct from traditional applications of biotechnology to health care and agriculture. Genencor ranks number 12 in revenues in the List of biotechnology companies. In 2008 Genencor entered a joint venture with DuPont, called DuPont Danisco Cellulosic Ethanol LLC, to develop and commercialize low cost technology for the production of cellulosic ethanol. In 2008, Genencor and Goodyear announced they are working to develop BioIsoprene. Wikipedia.
News Article | May 8, 2017
-- Molly B. Schmid, Ph.D., consultant for TriTech Small Business Development Center (SBDC), has been inducted into the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE). She was nominated, reviewed, and elected by peers and members of the College of Fellows for "outstanding contributions to research, translational development of novel products in start-up companies and teaching of entrepreneurship and business."AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. It is an organization of leaders in medical and biological engineering, consisting of academic, industrial, professional society councils and elected fellows.Dr. Schmid also is a member of the Inland Empire network of the Tech Coast Angels. She has specific expertise in early stage biotechnology companies, stemming from her own roles in scientific management, project leadership, and business development in three biotechnology companies.Her career has been about equally split between academia and industry. She was an assistant professor of Molecular Biology at Princeton University, and was also a professor and entrepreneur-in-residence at Keck Graduate Institute of Applied Life Sciences in Claremont Calif., where she taught courses in drug discovery and entrepreneurship. Prior to KGI, she was senior vice president of Preclinical Programs at Affinium Pharmaceuticals in Toronto, and held leadership positions at Genencor International and Microcide Pharmaceuticals.Dr. Schmid's experiences with these companies included securing venture capital, securing and managing multi-year, multi-million dollar corporate partnerships with Pfizer, Johnson & Johnson, Daiichi Pharmaceuticals, and several other smaller pharmaceutical and biotechnology companies, and playing leadership roles in growing and managing the scientific staff. These three biotech companies provided a wide range of experiences – two companies had IPO's, there were two compounds that entered clinical trials, and two companies ended in Chapter 11 reorganizations. She has nine issued U.S. patents, and several others pending while serving on numerous NSF and NIH grant review panels, and chairing a SBIR grant review panel for several years. She is also a Fellow of the American Academy of Microbiology, a Searle Scholar, and a Damon-Runyon Fellow.About TriTech SBDCTriTech is a Small Business Development Center (SBDC) (www.tritechsbdc.org)that works with high technology high growth firms by offering no cost consulting and training to entrepreneurs and businesses looking for go-to-market strategies that will accelerate the growth of their enterprise. TriTech also provides trainings and workshops on topics that are relevant and valuable to the business community. TriTech has assembled a team of professionals who prepare you for the funding process. TriTech also provides high level referrals to service providers and resources who give companies a competitive advantage. All of TriTech's services are provided at no cost to small businesses. For further information on TriTech SBDC, please contact Hanah Khaled at 951-571-6378 or hanahkhaled@ rccd.edu
Agency: European Commission | Branch: H2020 | Program: IA | Phase: BIOTEC-3-2014 | Award Amount: 11.39M | Year: 2015
Oxygen functionalities are key functional groups in many of todays chemicals and materials. The efficient introduction of oxygen-functionalities into raw materials are key chemical transformations in bulk and fine chemicals. Innovative bio-catalytic oxidation routes using molecular oxygen (from air) under benign and mild (pH) conditions such as ambient temperature and pressure can greatly improve the sustainability and economics of processes, but were so far mainly been applied in the pharma segments. In this segment, the enzyme-catalyzed step often represents the highest added value and the high price of the end-product (> 1000/kg) justifies less than optimal enzyme production and limitations in its catalytic efficiency. In order to achieve the widening of industrial application of enzymatic bio-oxidation processes to also larger volume but lower price chemical markets, ROBOX will demonstrate the techno-economic viability of bio-transformations of four types of robust oxidative enzymes: P450 monooxygenases (P450s), Baeyer-Villiger MonoOxygenase (BVMOs), Alcohol DeHydrogenase (ADH) and Alcohol OXidase (AOX) for which target reactions have already been validated on lab-scale in pharma, nutrition, fine & specialty chemicals and materials applications. ROBOX will demonstrate 11 target reactions on large scale for these markets in order to prepare them for scale up to commercial-scale plants. ROBOX is industry-driven with 2 major industrial players and 6 SMEs. It will assess the potential of technologies applied to become platform technologies technologies (multi-parameter screening systems, computational methodologies, plug bug expression systems) for broad replication throughout the chemical industry. The markets addressed within ROBOX represent a joint volume of over 6.000 ktons/year. The introduction of bio-oxidation processes is expected to bring substantial reductions in cost (up to -50%), energy use (-60%), chemicals (-16%) and GHG-emissions (-50%).
Agency: European Commission | Branch: H2020 | Program: BBI-IA-DEMO | Phase: BBI.VC2.D2-2015 | Award Amount: 11.17M | Year: 2016
The aim of PULPACKTION project is to develop cellulose-based tailored-to-purpose packaging solutions for specific food and electronic packaging applications which needs medium and high barrier requirements and that nowadays are packing in polymer fossil based solutions. This innovation will take advantage of the flexibility in the wet-moulding production of wood pulp based materials. Different types of wood pulp will be combined to prepare slurries for wet-moulding applications. These slurries will be additivated with biopolymers and other bio-based compounds in order to tailor the final properties of the resulting wet-moulded materials. By tailoring the composition of the wet mouldable slurry, a wide range of final properties in the resulting dry material will be achieved. This flexible packaging manufacturing system will be combined with 100% bio-based coatings and films on the cellulose-based substrate. To fulfil the properties required for PULPACKTIONs specific packaging applications using a fully bio-based approach, additional barriers will be implemented onto the wet moulded substrate. For this purpose, new bio-based polymer blends will be optimized. These new blends, containing biopolymers such as thermoplastic starch (TPS), poly (lactic acid) (PLA), other bio-additives, and reinforcements such as microfibrillated cellulose (MFC), will be processed into multilayer films, composites and coatings. In this manner, not only coatings for improved barrier properties, but also 100% bio-based films for packages top lids will be produced. Therefore, a final 100% bio-biobased integral packaging solution with similar properties to existing fossil-based packaging solutions will be achieved.
Agency: European Commission | Branch: H2020 | Program: BBI-IA-DEMO | Phase: BBI.D7-2015 | Award Amount: 6.61M | Year: 2016
Genencor International BV has recently developed a new enzyme product, C1-LC4, that in recent field trials has shown a promising 10% cost-reduction in the production of biogas from organic waste. Although the efficacy of the enzyme has clearly been shown, the current fermentation process does not provide sufficient yield in industrial production to be cost-effective for large-scale application. The objective of DEMETER is to increase the yield of this industrial fermentation process by at least 20%, improve the product recovery process by 40%, and reduce overall product cost by at least 15% while increasing the productivity of the process. In addition, DEMETER will demonstrate the efficacy of the enzyme in 8 field trials in biogas plants throughout Europe. The DEMETER consortium includes the entire value chain: enzyme producer Genencor International, enzyme retailer Miavit, the pilot plant BioBase Europe Pilot Plant, anaerobic digester expert OWS, independent biogas research centre DBFZ, Ciaotech for independent economic and environmental evaluation, and large farm, Biomoer, for field trials. DEMETER follows a multi-scale approach. First, the enzyme productivity will be improved on lab- and small pilot-scale, while obtaining insights for further scale-up. In parallel, the effect of enzymes on biogas yield will be quantified, using 5 commonly used biomass substrates. The improved fermentation and downstream process will be scaled up and demonstrated in a 15 000 L pilot plant. Finally, the improvement of the biogas production process due to the use of the C1-LC4 enzyme will be demonstrated in practice in 8 field trials. The results of these field trials will be fed back to further improve the production process and its yield. Ultimately, DEMETER will not only produce a fermentation process with increased yield, an improved product recovery process resulting in reduced production costs. The resulting product will lead to an increase in renewable biogas production in Europe.
Genencor | Date: 2013-04-24
The invention relates to apparatuses, machines, systems and methods for the recovery and purification of proteins, peptides, nucleic acids, biologically produced polymers and other compounds from aqueous fluids. The aqueous fluids can comprise enzyme concentrates and or a fermentation broth with or without cells or other starting material. The fermentation broth can be produced by fermentations of fungal, yeast, bacterial, mammalian, insect or plant cells.
Genencor | Date: 2013-04-17
The invention is directed to peptides. Specifically, the invention is directed to peptides which bind skin and do not bind hair. Alternatively, the invention is drawn to peptides which bind hair and do not bind skin.
Genencor | Date: 2014-05-21
Genencor | Date: 2012-03-14
Disclosed are variants of the -amylase derived from Bacillus sp. no. 707, compositions comprising said variants, compositions comprising the variants, and methods of using the variants. The methods of use include methods of cleaning surfaces, laundering textiles, desizing, hydrolyzing biofilms of various substrates, and treating starch (e.g., liquefaction and saccharification).
Genencor | Date: 2012-09-19
The present invention provides novel amylase variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel amylase variants, host cells comprising DNA encoding novel amylase variants, as well as methods for making amylases less allergenic. In addition, the present invention provides various compositions that comprise these amylase variants that are less immunogenic than the wild-type amylases.
Genencor | Date: 2012-07-02
Described are variants (mutants) of a parent alpha-amylase having alpha-amylase activity and exhibiting altered properties relative to the parent alpha-amylase, and methods of use, thereof.